These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37085637)

  • 1. Harmonizing Biopredictive Methodologies Through the Product Quality Research Institute (PQRI) Part I: Biopredictive Dissolution of Ibuprofen and Dipyridamole Tablets.
    Tsume Y; Ashworth L; Bermejo M; Cheng J; Cicale V; Dressman J; Fushimi M; Gonzalez-Alvarez I; Guo Y; Jankovsky C; Lu X; Matsui K; Patel S; Sanderson N; Sun CC; Thakral NK; Yamane M; Zöller L
    AAPS J; 2023 Apr; 25(3):45. PubMed ID: 37085637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction: Harmonizing Biopredictive Methodologies Through the Product Quality Research Institute (PQRI) Part I: Biopredictive Dissolution of Ibuprofen and Dipyridamole Tablets.
    Tsume Y; Ashworth L; Bermejo M; Cheng J; Cicale V; Dressman J; Fushimi M; Gonzalez-Alvarez I; Guo Y; Jankovsky C; Lu X; Matsui K; Patel S; Sanderson N; Sun CC; Thakral NK; Yamane M; Zöller L
    AAPS J; 2023 Jun; 25(4):58. PubMed ID: 37291273
    [No Abstract]   [Full Text] [Related]  

  • 3. Biopredictive tools for the development of injectable drug products.
    Villa Nova M; Gan K; Wacker MG
    Expert Opin Drug Deliv; 2022 Jun; 19(6):671-684. PubMed ID: 35603724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Biopredictive Dissolution Method for Extended-Release Desvenlafaxine Tablets.
    Carapeto GV; Duque MD; Issa MG; Ferraz HG
    Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Biopredictive Methods: A Workshop Summary Report.
    Pepin XJH; Dressman J; Parrott N; Delvadia P; Mitra A; Zhang X; Babiskin A; Kolhatkar V; Seo P; Taylor LS; Sjögren E; Butler JM; Kostewicz E; Tannergren C; Koziolek M; Kesisoglou F; Dallmann A; Zhao Y; Suarez-Sharp S
    J Pharm Sci; 2021 Feb; 110(2):567-583. PubMed ID: 32956678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
    Jamei M; Abrahamsson B; Brown J; Bevernage J; Bolger MB; Heimbach T; Karlsson E; Kotzagiorgis E; Lindahl A; McAllister M; Mullin JM; Pepin X; Tistaert C; Turner DB; Kesisoglou F
    Eur J Pharm Biopharm; 2020 Oct; 155():55-68. PubMed ID: 32781025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically Based Pharmacokinetics Modeling in Biopharmaceutics: Case Studies for Establishing the Bioequivalence Safe Space for Innovator and Generic Drugs.
    Wu D; Sanghavi M; Kollipara S; Ahmed T; Saini AK; Heimbach T
    Pharm Res; 2023 Feb; 40(2):337-357. PubMed ID: 35840856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development, validation and application of physiologically based biopharmaceutics model to justify the change in dissolution specifications for DRL ABC extended release tablets.
    Jaiswal S; Ahmed T; Kollipara S; Bhargava M; Chachad S
    Drug Dev Ind Pharm; 2021 May; 47(5):778-789. PubMed ID: 34082622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link-a Workshop Summary Report.
    Heimbach T; Suarez-Sharp S; Kakhi M; Holmstock N; Olivares-Morales A; Pepin X; Sjögren E; Tsakalozou E; Seo P; Li M; Zhang X; Lin HP; Montague T; Mitra A; Morris D; Patel N; Kesisoglou F
    AAPS J; 2019 Feb; 21(2):29. PubMed ID: 30746576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro-in vivo-in silico approach in biopharmaceutical characterization of ibuprofen IR and SR tablets.
    Beloica S; Cvijić S; Bogataj M; Parojčić J
    Eur J Pharm Sci; 2015 Jul; 75():151-9. PubMed ID: 25861718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of supersaturation level for oral absorption of BCS class IIb drugs, dipyridamole and ketoconazole, using in vivo predictive dissolution system: Gastrointestinal Simulator (GIS).
    Tsume Y; Matsui K; Searls AL; Takeuchi S; Amidon GE; Sun D; Amidon GL
    Eur J Pharm Sci; 2017 May; 102():126-139. PubMed ID: 28263914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current State and Challenges of Physiologically Based Biopharmaceutics Modeling (PBBM) in Oral Drug Product Development.
    Wu D; Li M
    Pharm Res; 2023 Feb; 40(2):321-336. PubMed ID: 36076007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of Biorelevant Pediatric Dissolution Methodology into PBPK Modeling to Predict In Vivo Performance and Bioequivalence of Generic Drugs in Pediatric Populations: a Carbamazepine Case Study.
    Pawar G; Wu F; Zhao L; Fang L; Burckart GJ; Feng K; Mousa YM; Al Shoyaib A; Jones MC; Batchelor HK
    AAPS J; 2023 Jun; 25(4):67. PubMed ID: 37386339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Extended-Release Formulations Containing Cyclobenzaprine Based on Physiologically Based Biopharmaceutics Modeling and Bioequivalence Safe Space.
    Miranda Dos Santos E; Ferraz HG; Issa MG; Duque MD
    J Pharm Sci; 2023 Dec; 112(12):3131-3140. PubMed ID: 37473918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen.
    Tsume Y; Langguth P; Garcia-Arieta A; Amidon GL
    Biopharm Drug Dispos; 2012 Oct; 33(7):366-77. PubMed ID: 22815122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards Virtual Bioequivalence Studies for Oral Dosage Forms Containing Poorly Water-Soluble Drugs: A Physiologically Based Biopharmaceutics Modeling (PBBM) Approach.
    Kambayashi A; Dressman JB
    J Pharm Sci; 2022 Jan; 111(1):135-145. PubMed ID: 34390740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies.
    Heimbach T; Kesisoglou F; Novakovic J; Tistaert C; Mueller-Zsigmondy M; Kollipara S; Ahmed T; Mitra A; Suarez-Sharp S
    J Pharm Sci; 2021 Dec; 110(12):3896-3906. PubMed ID: 34551349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Approach to Justify Dissolution Differences in an Extended Release Drug Product using Physiologically Based Biopharmaceutics Modeling and Simulation.
    Aishwarya R; Murthy A; Ahmed T; Chachad S
    J Pharm Sci; 2022 Jun; 111(6):1820-1832. PubMed ID: 35217007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report.
    Mackie C; Arora S; Seo P; Moody R; Rege B; Pepin X; Heimbach T; Tannergren C; Mitra A; Suarez-Sharp S; Borges LN; Kijima S; Kotzagiorgis E; Malamatari M; Veerasingham S; Polli JE; Rullo G
    Mol Pharm; 2024 May; 21(5):2065-2080. PubMed ID: 38600804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.